CIA
MGNX icon

Capital Impact Advisors’s MacroGenics MGNX Stock Holding History

Capital Impact Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-47,737
Closed -$976K – 196
2016
Q4 		$976K Hold
47,737
– – 0.4% 128
2016
Q3 		$1.43M Hold
47,737
– – 0.62% 36
2016
Q2 		$1.29M Hold
47,737
– – 0.6% 33
2016
Q1 		$895K Buy
47,737
+36,253
+316% +$690K 0.43% 131
2015
Q4 		$356K Hold
11,484
– – 0.17% 230
2015
Q3 		$246K Hold
11,484
– – 0.12% 231
2015
Q2 		$436K Hold
11,484
– – 0.2% 205
2015
Q1 		$360K Buy
+11,484
New +$389K 0.16% 223

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Capital Impact Advisors's MGNX Position: Q1 2017 in Review

Capital Impact Advisors sold out of MacroGenics (MGNX) in Q1 2017, closing a stake of 47,737 shares — an estimated $976K sold.

Capital Impact Advisors first reported a position in MGNX in Q1 2015 and held it in 8 quarters. The position peaked at $1.43M in Q3 2016. 111 funds tracked by Wall St. Rank hold MGNX as of Q1 2017.

  • Capital Impact Advisors reported no remaining MacroGenics position as of Q1 2017 after selling out during the quarter.
  • Capital Impact Advisors sold 47,737 MacroGenics shares in Q1 2017, an estimated $976K.
  • Capital Impact Advisors first reported a position in MacroGenics in Q1 2015 and held it in 8 quarters.
  • Capital Impact Advisors's MacroGenics position peaked at $1.43M in Q3 2016.
  • 111 funds tracked by Wall St. Rank held MacroGenics as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.